Reuters logo
BRIEF-Cel-Sci gives update on partial clinical hold on phase 3 head and neck cancer study with multikine
March 6, 2017 / 1:21 PM / 7 months ago

BRIEF-Cel-Sci gives update on partial clinical hold on phase 3 head and neck cancer study with multikine

March 6 (Reuters) - Cel-sci Corp

* Cel-Sci gives update on partial clinical hold on phase 3 head and neck cancer study with multikine

* Cel-Sci - pursuant to partial clinical hold, patients currently receiving study treatments can continue to receive treatment at discretion of physicians

* Cel-Sci - patients already enrolled in multikine drug study will continue to be followed

* Cel-Sci-To provide updated investigator’s brochure, procedures for compliance with requirements under 21 cfr 312 subpart d to address partial clinical hold

* Cel-Sci - to provide to FDA list of major protocol deviations, which cel-sci believes will “affect study results”

* Cel-Sci - to provide FDA a plan to identify major protocol deviations across all patients enrolled in phase 3 protocol for multikine drug Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below